[go: up one dir, main page]

DK1428534T3 - Benzofurazanderivater til forögelse af glutaminerge synaptiske responser - Google Patents

Benzofurazanderivater til forögelse af glutaminerge synaptiske responser

Info

Publication number
DK1428534T3
DK1428534T3 DK04075259T DK04075259T DK1428534T3 DK 1428534 T3 DK1428534 T3 DK 1428534T3 DK 04075259 T DK04075259 T DK 04075259T DK 04075259 T DK04075259 T DK 04075259T DK 1428534 T3 DK1428534 T3 DK 1428534T3
Authority
DK
Denmark
Prior art keywords
enhancing
receptors
compounds
synaptic responses
ampa
Prior art date
Application number
DK04075259T
Other languages
English (en)
Inventor
Christopher M Marrs
Gary A Rogers
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1428534T3 publication Critical patent/DK1428534T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Luminescent Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK04075259T 1997-02-13 1998-02-13 Benzofurazanderivater til forögelse af glutaminerge synaptiske responser DK1428534T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses
EP98906358A EP0960105B1 (en) 1997-02-13 1998-02-13 Benzofurazan compounds that enhance ampa receptor activity

Publications (1)

Publication Number Publication Date
DK1428534T3 true DK1428534T3 (da) 2006-06-12

Family

ID=25177504

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98906358T DK0960105T3 (da) 1997-02-13 1998-02-13 Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet
DK04075259T DK1428534T3 (da) 1997-02-13 1998-02-13 Benzofurazanderivater til forögelse af glutaminerge synaptiske responser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98906358T DK0960105T3 (da) 1997-02-13 1998-02-13 Benzofurazanforbindelser, der foröger AMPA-receptoraktivitet

Country Status (24)

Country Link
US (3) US6110935A (da)
EP (2) EP1428534B1 (da)
JP (1) JP4446023B2 (da)
KR (1) KR100544295B1 (da)
CN (1) CN1085206C (da)
AT (2) ATE326221T1 (da)
AU (1) AU737802C (da)
BR (1) BR9807333B1 (da)
CA (1) CA2279319C (da)
CZ (1) CZ299765B6 (da)
DE (2) DE69834590T2 (da)
DK (2) DK0960105T3 (da)
ES (2) ES2264078T3 (da)
GB (1) GB2325225B (da)
HU (1) HUP0002303A3 (da)
ID (1) ID22342A (da)
IL (1) IL131200A (da)
NO (1) NO318935B1 (da)
NZ (1) NZ336980A (da)
PL (1) PL199135B1 (da)
PT (2) PT960105E (da)
RU (1) RU2189984C2 (da)
TR (1) TR199901941T2 (da)
WO (1) WO1998035950A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (da) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
WO2004062616A2 (en) * 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
DE602004011515T2 (de) * 2003-05-23 2009-01-29 Basilea Pharmaceutica Ag Furazanobenzimidazole
EP1715863B1 (en) * 2004-01-26 2012-05-09 Cortex Pharmaceuticals, Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
BRPI0716375A2 (pt) 2006-08-31 2013-10-15 Univ Alberta Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...
PT2144506E (pt) * 2007-01-03 2011-12-21 Servier Lab Composto de [1,2,3]-benzotriazinona substituída em posição 3 para aumentar as respostas glutamatérgicas nas sinapses
AU2007342364A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
EA200901546A1 (ru) 2007-05-17 2010-04-30 Кортекс Фармасеутикалс, Инк. Дизамещенные амиды для усиления глутаматергических синаптических ответов
CA2702292A1 (en) * 2007-08-10 2009-02-19 Rudolf Mueller Bicyclic amides for ehancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
WO2010054336A2 (en) * 2008-11-10 2010-05-14 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
KR20110115139A (ko) * 2009-02-02 2011-10-20 코텍스 파마슈티칼스, 인크. 글루타메이트성 시냅틱 반응을 향상시키기 위한 비시클릭 아미드 유도체
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1H-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
US20150011554A1 (en) 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
SU1657189A1 (ru) * 1988-05-23 1991-06-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ коррекции апато-абулических состо ний при шизофрении
SU1587050A1 (ru) * 1988-12-23 1990-08-23 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Производные (7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амина в качестве промежуточных продуктов в синтезе 2-[(7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амино]-5-бром-N-(4-хлорфенил)бензамида, обладающего антигельминтной активностью
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
CA2450801C (en) * 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
KR100544295B1 (ko) 2006-01-23
ID22342A (id) 1999-09-30
EP1428534A1 (en) 2004-06-16
US6730677B2 (en) 2004-05-04
RU2189984C2 (ru) 2002-09-27
US6313115B1 (en) 2001-11-06
CN1085206C (zh) 2002-05-22
JP4446023B2 (ja) 2010-04-07
DE69834590D1 (de) 2006-06-22
CA2279319A1 (en) 1998-08-20
DK0960105T3 (da) 2004-08-30
EP0960105A1 (en) 1999-12-01
GB2325225B (en) 1999-03-03
US20020055508A1 (en) 2002-05-09
NO993768D0 (no) 1999-08-04
ATE326221T1 (de) 2006-06-15
DE69834590T2 (de) 2007-04-26
CA2279319C (en) 2008-08-05
ATE266649T1 (de) 2004-05-15
PL335058A1 (en) 2000-03-27
ES2264078T3 (es) 2006-12-16
GB2325225A (en) 1998-11-18
PT1428534E (pt) 2006-07-31
HUP0002303A2 (hu) 2001-04-28
CZ299765B6 (cs) 2008-11-19
IL131200A0 (en) 2001-01-28
ES2221152T3 (es) 2004-12-16
CN1247534A (zh) 2000-03-15
US6110935A (en) 2000-08-29
IL131200A (en) 2005-06-19
AU737802B2 (en) 2001-08-30
HUP0002303A3 (en) 2002-09-30
PT960105E (pt) 2004-09-30
BR9807333B1 (pt) 2011-10-18
AU737802C (en) 2005-05-12
NO318935B1 (no) 2005-05-30
EP0960105B1 (en) 2004-05-12
AU6159998A (en) 1998-09-08
KR20000071082A (ko) 2000-11-25
PL199135B1 (pl) 2008-08-29
EP1428534B1 (en) 2006-05-17
DE69823803D1 (de) 2004-06-17
CZ279599A3 (cs) 2000-01-12
JP2001512459A (ja) 2001-08-21
GB2325225A8 (en) 1999-02-17
BR9807333A (pt) 2000-04-18
WO1998035950A1 (en) 1998-08-20
TR199901941T2 (xx) 1999-12-21
DE69823803T2 (de) 2005-04-14
GB9809221D0 (da) 1998-07-01

Similar Documents

Publication Publication Date Title
DK1428534T3 (da) Benzofurazanderivater til forögelse af glutaminerge synaptiske responser
BR9106665A (pt) Derivados de quinuclidina
ATE232522T1 (de) Piperazin-derivate und ihre verwendung als entzündungshemmende mittel
AU2427497A (en) Benzoxazines for enhancing synaptic response
ATE451362T1 (de) Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten
ES2191076T3 (es) Nuevos derivados de 1-aril-pirazol y su empleo como plaguicidas.
ATE481103T1 (de) Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
DK1054673T3 (da) Benzoxazinforbindelser til forstærkelse af synaptisk reaktion
DK1067935T3 (da) Acylbenzoxaziner til forstærkning af synaptisk(e) reaktion(er)
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
ATE112557T1 (de) Azetidinderivate, zusammensetzungen und ihre verwendung.
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
DK0556152T3 (da) Pyridiniumderivater og deres anvendelse til bestemmelse af bindevævssygdomme hos mennesker og dyr
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ATE47841T1 (de) 5-sulfonamido-1-aryl-pyrazole.
CA2249654A1 (en) Benzoxazines for enhancing synaptic response
TH28200B (th) การใช้ (สูตร) il -อะโกนิสท์สำหรับรักษาการกลั้นปัสสาวะไม่อยู่